The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Nass R, Blakely RD (2003) Annu Rev Pharmacol Toxicol 43: 521-44 M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ (2015) Neuron 88: 762-73 Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. Hansen FH, Skjørringe T, Yasmeen S, Arends NV, Sahai MA, Erreger K, Andreassen TF, Holy M, Hamilton PJ, Neergheen V, Karlsborg M, Newman AH, Pope S, Heales SJ, Friberg L, Law I, Pinborg LH, Sitte HH, Loland C, Shi L, Weinstein H, Galli A, Hjermind LE, Møller LB, Gether U (2014) J Clin Invest 124: 3107-20 Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, Carl YT, Bloch B, Kook S, Aubert I, Dovero S, Doudnikoff E, Gurevich VV, Gurevich EV, Bezard E (2010) Sci Transl Med 2: 28ra28 Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA (2011) Brain 134: 2339-57 SLC30A10 is a cell surface-localized manganese efflux transporter, and parkinsonism-causing mutations block its intracellular trafficking and efflux activity. Leyva-Illades D, Chen P, Zogzas CE, Hutchens S, Mercado JM, Swaim CD, Morrisett RA, Bowman AB, Aschner M, Mukhopadhyay S (2014) J Neurosci 34: 14079-95 Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Garcia BG, Neely MD, Deutch AY (2010) Cereb Cortex 20: 2423-32 L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV (2005) Neurobiol Dis 18: 323-35 Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. Sköld K, Svensson M, Nilsson A, Zhang X, Nydahl K, Caprioli RM, Svenningsson P, Andrén PE (2006) J Proteome Res 5: 262-9 Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice. Zurkovsky L, Bychkov E, Tsakem EL, Siedlecki C, Blakely RD, Gurevich EV (2013) Dis Model Mech 6: 171-83 Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease. Bajpai P, Sangar MC, Singh S, Tang W, Bansal S, Chowdhury G, Cheng Q, Fang JK, Martin MV, Guengerich FP, Avadhani NG (2013) J Biol Chem 288: 4436-51 Neuroinvasive Nocardia asteroides GUH-2 induces apoptosis in the substantia nigra in vivo and dopaminergic cells in vitro. Tam S, Barry DP, Beaman L, Beaman BL (2002) Exp Neurol 177: 453-60 G protein-coupled receptor kinases as regulators of dopamine receptor functions. Gurevich EV, Gainetdinov RR, Gurevich VV (2016) Pharmacol Res 111: 1-16 Diminished taxol/GTP-stimulated tubulin polymerization in diseased region of brain from patients with late-onset or inherited Alzheimer's disease or frontotemporal dementia with parkinsonism linked to chromosome-17 but not individuals with mild cognitive impairment. Boutté AM, Neely MD, Bird TD, Montine KS, Montine TJ (2005) J Alzheimers Dis 8: 1-6 The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Johnson KA, Jones CK, Tantawy MN, Bubser M, Marvanova M, Ansari MS, Baldwin RM, Conn PJ, Niswender CM (2013) Neuropharmacology 66: 187-95 Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA (2015) Neuropharmacology 95: 121-9 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Ferguson MC, Nayyar T, Deutch AY, Ansah TA (2010) Neuropharmacology 59: 31-6 Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Brown AM, Deutch AY, Colbran RJ (2005) Eur J Neurosci 22: 247-56 Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation. Nayyar T, Bubser M, Ferguson MC, Neely MD, Shawn Goodwin J, Montine TJ, Deutch AY, Ansah TA (2009) Eur J Neurosci 30: 207-16 Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Deutch AY, Colbran RJ, Winder DJ (2007) Parkinsonism Relat Disord 13 Suppl 3: S251-8 Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features. Kwakye GF, Paoliello MM, Mukhopadhyay S, Bowman AB, Aschner M (2015) Int J Environ Res Public Health 12: 7519-40 In-vivo PET imaging of implanted human retinal pigment epithelium cells in a Parkinson's disease rat model. Wang R, Zhang J, Guo Z, Shen L, Shang A, Chen Y, Yao S, He T, Yin D, Tian J (2008) Nucl Med Commun 29: 455-61
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.